Zacks Investment Research upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a sell rating to a hold rating in a report released on Monday morning, Zacks.com reports.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

Several other research analysts have also commented on the company. Needham & Company LLC reiterated a buy rating on shares of Collegium Pharmaceutical in a report on Tuesday, December 29th. HC Wainwright raised their price objective on Collegium Pharmaceutical from $29.00 to $33.00 and gave the stock a buy rating in a research report on Monday. Finally, BidaskClub downgraded Collegium Pharmaceutical from a buy rating to a hold rating in a research report on Thursday, October 22nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $28.86.

Shares of COLL stock opened at $21.83 on Monday. The stock’s fifty day moving average is $19.56 and its two-hundred day moving average is $18.89. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.01 and a current ratio of 1.08. The firm has a market capitalization of $754.93 million, a P/E ratio of 44.55, a PEG ratio of 0.65 and a beta of 1.27. Collegium Pharmaceutical has a fifty-two week low of $13.00 and a fifty-two week high of $25.59.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.58). Collegium Pharmaceutical had a return on equity of 12.64% and a net margin of 5.71%. The company had revenue of $77.40 million for the quarter, compared to analysts’ expectations of $77.39 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. The firm’s revenue was up 6.2% on a year-over-year basis. On average, equities analysts forecast that Collegium Pharmaceutical will post 0.92 earnings per share for the current year.

In related news, CTO Alison B. Fleming sold 5,967 shares of the business’s stock in a transaction that occurred on Thursday, December 3rd. The stock was sold at an average price of $19.24, for a total transaction of $114,805.08. Following the completion of the sale, the chief technology officer now owns 111,419 shares in the company, valued at $2,143,701.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CTO Alison B. Fleming sold 16,042 shares of the business’s stock in a transaction that occurred on Thursday, January 7th. The stock was sold at an average price of $22.00, for a total value of $352,924.00. Following the sale, the chief technology officer now owns 114,755 shares of the company’s stock, valued at approximately $2,524,610. The disclosure for this sale can be found here. 8.08% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of COLL. Advisor Group Holdings Inc. grew its holdings in Collegium Pharmaceutical by 104.5% during the second quarter. Advisor Group Holdings Inc. now owns 1,395 shares of the specialty pharmaceutical company’s stock worth $25,000 after acquiring an additional 713 shares during the period. Nisa Investment Advisors LLC grew its holdings in Collegium Pharmaceutical by 332.2% during the third quarter. Nisa Investment Advisors LLC now owns 3,112 shares of the specialty pharmaceutical company’s stock worth $65,000 after acquiring an additional 2,392 shares during the period. Great West Life Assurance Co. Can grew its holdings in Collegium Pharmaceutical by 58.9% during the third quarter. Great West Life Assurance Co. Can now owns 3,614 shares of the specialty pharmaceutical company’s stock worth $99,000 after acquiring an additional 1,340 shares during the period. BNP Paribas Arbitrage SA grew its holdings in Collegium Pharmaceutical by 539.5% in the third quarter. BNP Paribas Arbitrage SA now owns 7,892 shares of the specialty pharmaceutical company’s stock valued at $164,000 after purchasing an additional 6,658 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Collegium Pharmaceutical in the third quarter valued at $204,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting.

Recommended Story: Stock Split

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.